Content about Impax Pharmaceuticals

February 23, 2012

FDA accepts NDA filing for Impax's Parkinson's disease treatment

The Food and Drug Administration has accepted a new drug application for the treatment of idiopathic Parkinson’s disease.

February 1, 2012

Impax licenses migraine drug rights from AstraZeneca

Impax Pharmaceuticals said Wednesday that it obtained exclusive U.S. commercial rights to a drug for migraine headaches made by AstraZeneca.

August 15, 2011

Study: Investigational GSK, Impax drug reduces Parkinson's symptoms

Patients taking an experimental treatment for Parkinson's disease experienced greater reduction in symptoms than those taking standard therapies, according to results of a late-stage clinical trial.

July 26, 2011

Impax enrolls patients into late-stage trial for Parkinson's treatment

The branded drugs division of Impax Labs has finished enrolling patients in a late-stage trial of a drug for Parkinson’s disease.

April 1, 2011

Impax says Parkinson's disease treatment is safe, effective

An investigational drug for Parkinson’s disease was safe and effective, according to results of a late-stage clinical trial scheduled for presentation next week.

December 16, 2010

GSK, Impax ink licensing deal for Parkinson's drug

GlaxoSmithKline will pay Impax Pharmaceuticals $11.5 million upfront to exclusively sell Impax's investigational Parkinson’s disease treatment.